Researchers at the University of California San Diego have begun the first double-blind, randomised, placebo-controlled trial of the efficacy and safety of cannabis as a treatment for acute migraines.

Currently, 20 participants experiencing monthly migraines are enrolled in the trial, with the aim to recruit up to 90 volunteers in total.

Research lead Nathaniel Schuster said: “Many patients who suffer from migraines have experienced them for years, but have never discussed them with their physicians. They are self-treating with various treatments such as cannabis.

“Right now, when patients ask us if cannabis works for migraines, we do not have evidence-based data to answer that question.”

The trial volunteers will be separated into four groups, with one receiving a vape with sham cannabis, another taking four puffs of cannabis flower containing THC, a third group taking four puffs of cannabis flower containing CBD, and a fourth group vaping a mix of THC and CBD.

Researchers will then determine which treatment is best for relieving headache pain, nausea, vomiting and light/sound sensitivity in the short and long term.

Prior to launching Cannabiz, Martin was co-founder and CEO of Asia-Pac’s leading B2B media and marketing information brand Mumbrella, overseeing its sale to Diversified Communications in 2017. A journalist...